At AstraZeneca, we love the passionate beat of collaboration and the unpredictable rhythm of innovation.
At the heart of the AstraZeneca site in Gothenburg, Sweden, we are proud to open up the BioVentureHub – giving emerging biotech/medtech companies and academic groups a unique opportunity to co-locate and interact with big pharma, and each other, to advance the life sciences.
As in a dance, we combine our styles, skills and embellishments to create something beautiful, passionate and endlessly exciting. With our expertise and experience we can lead - we love to lead. We’re equally happy to follow...
We know that we both have important things to contribute.
Seminar: Strategies for drug development
CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub
WHAT’S IN IT FOR YOU?
Embedded at the heart of AstraZeneca Gothenburg, you become part of a unique, open and collaborative scientific community. BioVentureHub members have the same access
to the facilities as AstraZeneca staff.
Access to scientific leadership
Locating your business in the BioVentureHub at AstraZeneca Gothenburg, you can tap into the power of AstraZeneca’s world-class scientists and state-of-the art, ‘big pharma’ lab facilities and infrastructure.
Open doors and open innovation
AstraZeneca Gothenburg is an integrated discovery and development site built to facilitate open innovation and spontaneous interactions. AstraZeneca has invested heavily in open innovation, including access to compound libraries and screening technologies.
Being part of the BioVentureHub and co-locating with AstraZeneca helps you grow a stronger and more successful life science business. The road to market becomes less risky and costly.
A great place to work
As one of three strategic AstraZeneca R&D centres, and with a rich scientific heritage, AstraZeneca Gothenburg is more than just a great place to work. It is a vibrant, diverse and open environment in which you and your business can thrive.
A great place to live
With its seaside setting and close proximity to cultural and natural attractions, Gothenburg - the second largest city in Sweden – fully deserves all the recognition it gets as a top travel destination, and a clean, well-functioning place for you to live and enjoy. Check out the 'Move to Gothenburg' website.
Unique service offering
At the BioVentureHub, you get access to everything that AstraZeneca gets – from chemical supplies thru shared services and business support to rubber gloves. Our facilities live and breathe life science - everything about the site is optimised to enable business success.
Access to world-class scientific and technical skills
AstraZeneca Gothenburg features all the skills and capabilities you need to take drug projects from early discovery to launch. This includes everything from early medicinal chemistry and in vitro/vivo biology through drug safety and metabolism to pharmaceutical and clinical development.
Several specialised skills such as computational biology, transgenics, personal healthcare and biomarkers are represented at the site, to mention just a few. We also have specialised on-site expertise across the entire discovery and development value chain when it comes to respiratory/inflammation, autoimmunity, cardiovascular and metabolic diseases therapy areas - including a centre of excellence for inhalation.
“By acting in an environment with the competence and experience present at the BioVentureHub and AstraZeneca, we expect to reduce inherent development risks in the project and that our efforts will yield results much more quickly.”
- Henrik Nittmar, CEO of Corline Biomedical AB
How independently can you run your company in the BioVentureHub?
The BioVentureHub is a community of trust. We will ask you to enter into a basic rental agreement with AstraZeneca. The rental agreement defines facility-related rights and obligations, and includes a confidentiality policy. The rental agreement does not give AstraZeneca any rights to your company information nor to potential inventions/IP – not even a “first right of refusal”. As such, you have full freedom to operate as an independent company. No strings attached.
Would your company fit in?
Whether you are biotech, medtech, e-health, academia... the core principle permeating throughout the BioVentureHub is that you share a collaborative and open attitude built on mutual respect, innovation and scientific curiosity.
The BioVentureHub is an ideal growth catalyst for companies that have just entered or are about to enter the development phase.
AstraZeneca’s BioVentureHub was established in 2014 as an innovative ecosystem to further strengthen the life science industry in Scandinavia.
Ideal for emerging biotech and medtech businesses and academic groups. 18 companies, 1 academic group, 4 external sponsors, 2 scientific partners already onboard.
Approx. 2,800 m2 office & lab space in central site location. AstraZeneca Gothenburg employs approx. 2,600 people, including 600 Ph.D. scientists
Why is AstraZeneca doing this?
AstraZeneca set up the BioVentureHub to further strengthen the life science ecosystem in Scandinavia. Using resources and capacity in a new way, the hub exposes AstraZeneca to more innovation and science. It stimulates an even more vibrant place to work and generates future collaboration opportunities. More dance partners is a positive side effect!
“Combining different value chains, ideas and perspectives in the same place, our vision is to generate a climate of open innovation that will help grow and nurture the Scandinavian life science ecosystem.”
- Magnus Björsne, AstraZeneca BioVentureHub
Meet the companies
We enable decision-makers in clinical drug development to optimize outcomes and minimize risk in Phase 1b and Phase 2 trials by the use of advanced imaging techniques. We also provide expert support for product differentiation in life cycle management. We specialize in cardio-metabolic conditions and oncology/immuno-oncology.
Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, the fully human antibody PC-mAb, is in clinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit.
CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. www.cellink.com
Cereno Scientific is committed to intelligent thrombosis prevention. The company is developing an innovative pharmaceutical to strengthen the body's own intelligent defence system to prevent blood clots - to be used globally in the treatment of thrombosis-related cardiovascular diseases. www.cerenoscientific.com
Corline Pharma is a subsidiary to Corline Biomedical AB, a Nasdaq/OMX First North (CLBIO) listed company that develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Corline Pharma has been formed with the aim of exploring and evaluating new indications.
Ectin Research is a cancer therapy company with a technology based on repositioning of approved drugs and an initial efficacy observation in a bladder cancer patient with spread and incurable disease. The initial aim of the company is to focus on treating metastasized bladder cancer to prove the efficacy of the therapy. Following this, Ectin Research plans to explore the treatment of other cancer indications. www.ectinresearch.com
Emeriti Bio AB is a privately held sister company to Emeriti Pharma AB. The focus is on novel treatment options for heavy menstrual bleeding. Emeriti Bio AB is also developing molecules for validated pharmaceutical drug targets in different areas. Finally, Emeriti Bio AB provides consultancy services in chemistry, drug discovery and drug development.
Emeriti Pharma AB is a privately held sister company to Emeriti Bio AB. Emeriti Pharma is focused on the development of EP0003 for dermatology, a compound originally acquired from AstraZeneca. EP0003 will start phase I in Q3-2016. www.emeritipharma.se
ForValue AB is a consultancy company in the medical devices area. Our consultants have long practical experience and broad, as well as specific, specialities that are combined in seamless solutions across competences (quality management, product development, clinical data, risk management, biocompatibility and the regulatory framework).
Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. Inorbit focuses currently on compounds for the treatment of Type 2 Diabetes Mellitus, Gout, Fatty Liver Disease (NAFLD / NASH), and inflammatory diseases. Read more at https://inorbittx.com/
In Singulo Solutions
In Singulo Solutions develops next generation biosensing platforms for drug discovery based on single molecule microscopy. The In Singulo platform opens new avenues to biophysically characterize challenging drug targets such as membrane proteins.
I-Tech, develops, manufacture and market an antifouling substance, Selektope. Selektope has proven remarkable fouling protection even in the most demanding situations and in very low concentrations in marine paints. Our vision is to be a global developer and supplier of marine biocides with an extended market share.
Lipigon is a lipid biology specialist company, utilizing its proprietary and unique know-how and technologies to discover and develop novel therapies for patients with lipid disorders and other cardiometabolic risk factors.
MentorMate develops digital health, mobile and web applications. With over 400 employees in seven locations in the US and Europe, MentorMate helps clients build effectively and deliver robust experiences while managing total cost-of-ownership. www.mentormate.com
Addressing the microbiome, MetaboGen is creating breakthrough opportunities to develop novel therapeutics and next generation probiotics. The company was founded based on world leading science from the labs of Professor Fredrik Bäckhed (University of Gothenburg) and Professor Jens B Nielsen (Chalmers University of Technology), to provide commercial access to metagenome research and development. www.metabogen.se
Metynex is a new company committed to the development of pharmaceuticals in the cardiometabolic area. The company has expertise in both preclinical and early clinical development in this therapeutic area. A new principle for treatment of type II diabetes is under development. The substance improves peripheral insulin sensitivity and also reduces the risk of the co-morbidities that are common in diabetics.
Mölnlycke is a world leading medical solutions company. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings. Learn more at www.molnlycke.com
Chalmers University of Technology/Gothenburg University have located their NanoSIMS laboratory in the BioVentureHub. The lab offers unique, ultra-high spatial chemical imaging giving true sub-cellular localisation of molecules in cells and tissue, as well as quantitative isotopic imaging for many other applications ranging from geology to materials science.
Building on a spin out from AstraZeneca, OnDosis is developing a smart drug delivery platform for personalized and connected dosing of medicines. The OnDosis devices combine tailored and flexible dosing and mobile health technologies with the objective to improve treatment outcomes for a wide array of diseases and patients. The first OnDosis product is under development with the aim to reach the market in 2020. www.ondosis.com
Promimic has developed a process that makes it possible to modify all types of implant materials and geometries with a nanometer-thin surface of synthetic bone minerals; HAnano Surface. It is based on the substance hydroxyapatite (HA), which by size, shape, structure and chemistry mimics the living bone tissue. The HAnano Surface is licensed to dental and orthopaedic implants companies. Promimic is a spin-off company based on research from Chalmers University of Technology. www.promimic.com
Q&Q Labs is a contract laboratory for custom research services within the field of organic analytical chemistry. Our main focus is to provide analysis services of active substances to producers of pharmaceuticals, medical device and food supplements.
RLS Global AB is a medtech life science company. Based on the company's unique hypochlorite platform, RLS develops and sells products for some of the most common diseases within dental and wound care. RLS Global’s current portfolio includes brands such as ChloraSolv®, Perisolv®, Carisolv® och Kindersolv®. The company is listed on the Nasdaq First North stock exchange. www.rlsglobal.se
Swecure is focused on human development, with its lead candidate being a preventive treatment for allergy. The company is also developing a composition of bacteria shown to be lower in patients with IBD and IBS that work by modulating the human microbiome. Swecures products epitomize this: it uses good microbes to treat various diseases.
Synergon offers qualified strategic IP advice and IP portfolio management, with a focus on protection of commercially viable IP, keeping costs at a minimum. We see the big picture around Intellectual Property (IP) from a business-oriented perspective within the Life Science, biotechnology and IT sectors. www.synergon.se
Vicore Pharma is a drug-development company at the cutting edge of international research on the AT2 receptor. The company’s portfolio comprises small molecules with clinical applicability in disease areas in need of anti-fibrosis, anti-inflammation, neuroprotection, neuroregeneration and cardiovascular protection.
“AstraZeneca’s BioVentureHub is an exciting innovation model for strengthening competitiveness and collaboration in the life science industry. It’s smart Swedish industry in action, serving as inspiration to other companies and industries when it comes to generating opportunities in the new industrial era.”
- Mikael Damberg, Swedish minister for enterprise and innovation